Immunogenic and protective response in mice immunized with a purified, inactivated, dengue-2 virus vaccine prototype made in fetal rhesus lung cells

American Journal of Tropical Medicine and Hygiene

Volumn 55, Issue 5, 1996, Pages 504-510

  Putnak, Robert ^a,c   Cassidy, Kevin ^a   Conforti, Nadia ^a   Lee, Raymond ^a   Sollazzo, Domenic ^a   Truong, Tran ^a   Ing, Esther ^a   Dubois, Doria ^b   Sparkuhl, Joachim ^a   Gastle, William ^a   Hoke, Charles ^a  

^a Microbix Biosystems Inc   (Canada)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^c WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM HYDROXIDE; FREUND ADJUVANT; INACTIVATED VACCINE; NEUTRALIZING ANTIBODY; SILVER; SUCROSE; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ARTICLE; DENGUE VIRUS; FETUS; IMMUNIZATION; IMMUNOBLOTTING; IMMUNOGENICITY; LUNG ALVEOLUS CELL; MOUSE; NONHUMAN; POLYACRYLAMIDE GEL ELECTROPHORESIS; SEROTYPE; SILVER STAINING; SUBCUTANEOUS DRUG ADMINISTRATION; SUCROSE GRADIENT; VIROGENESIS; VIRUS INACTIVATION;

ANIMALIA; DENGUE VIRUS; DENGUE VIRUS TYPE 2;

EID: 10544232608     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1996.55.504     Document Type: Article

References (31)

1. Henchal FA, Putnak JR, 1990 The dengue viruses. Clin Microbiol Rev 3: 376-396.
2. Monath TP, 1990. Flaviviruses. Fields BN, Knipe DM, Chanock RM, Hirsch MS, Melnick JL, Monath TP, Roizman B, Fields Virology. Second edition. Volume I. New York: Raven Press, 763-814.
3. Halstead SB, 1965. Mosquito-borne hemorragic fevers of South and Southeast Asia: with discussion by Max Theiler. Yale J Biol Med 37: 434-454.
4. Westaway EC, Brinton MA, Gaimamovich S, Horzinek MC, Igarashi A, Kaariainen L, Lvov DK, Porterfield JS, Russell PK, Trent DW, 1985. Flaviviridae Intervirology 124: 183-192.
5. Calisher CH, Karabatsos N, Dalrymple JM, Shope RE, Porterfield JS, Westaway EC, Brandt WE, 1989. Antigenic relationships betweeen fiaviviros as determined by cross-neutralization tests with polyclonal antisera J Gen Virol 70: 37-43.
6. Chambers TJ, Hahn CS, Galler R, Rice CM, 1990. Flavivirus genome organization, expression, and replication. Annu Rev Microbiol 44: 649-688.
7. Qureshi AA, Trent DW, 1973. Group B arbovirus structural and nonstructural antigens III. Serological specificity of solubilized intracellular viral proteins. Infect Immun 18: 993-999.
8. Gentry MK, Henchal EA, McCown JM, Brandt WE, Dalrymple JM. 1982. Identification of distinct antigenic determinants of dengue 2 virus using monoclonal antibodies. Am J Trop Med Hyg 31: 548-555.
9. Simmons JS, St. John JH, Reynolds FHK. 1931 Experimental studies of Dengue. Brown WH, ed. Monographs of the Bureau of Science, Monograph 29. Manila, The Philippines: Manila Bureau of Printing, 1-489.
10. Sabin AB, Schlesinger RW, 1945. Production of immunity to dengue with virus modified by propagation in mice. Science 101: 640-642
11. Eckels KH, Harrison IF, Summers PL, Russell PK, 1980. Dengue-2 vaccine: preparation from a small-plaque virus clone. Infect Immun 27: 175-180.
12. Eckels KH, Scott RM, Bancroft WH, Dubois DR, Summer PL, Russell PK, Halstead SB, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. V. Human response to immunization with a candidate vaccine prepared in fetal rhesus lung cells. Am J Trop Med Hyg 33: 684-689.
13. Halstead SB, Eckels KH, Putvatana R. Larsen LK, Marchette NJ, 1984. Selection of attenuated dengue 4 viruses by serial passage in primary kidney cells. IV. Characterization of a vaccine candidate in fetal rhesus lung cells. Am J Trop Med Hyg 33: 679-683.
14. Bancroft WH, Scott RM, Eckels KH, Hoke CH, Simms TE, Jesrani KDT, Summers PL, Dubois DR, Tsoulos D, Russell PK, 1984. Dengue virus type 2 vaccine: reactogenicity and immunogenicity in soldiers. J Infect Dis 149: 1005-1010.
15. Bhamarapravati N, Yoksan S, Chayaniyayothin T, Angsubphak- orn S, Bunyaratvej A, 1987. Immunization with a live attentuated dengue-2-virus candidate vaccine (16681-PDK 53): clinical, immunological and biological responses in adult volunteers. Bull World Heath Organ 65: 189-195
16. Bhamarapravati N, Yoksan S, 1989. Study of bivalent dengue vaccine in volunteers. Lancer i: 1077.
17. Hoke CH Jr. Malinoski FJ, Eckels KH, Scott RM, Dubois DR, Summers PL, Simms T, Burrous J, Hasty SE, Bancroft WH. 1990 Preparation of an attenuated dengue 4 (341750 Carib) virus vaccine. II. Safety and immunogenicity in humans. Am J Trop Med Hyg 43: 219-226.
18. Edelman R, Tacket CO, Wasserman SS, Vaughn DW, Eckels KH, Dubois DR, Summers PL, Hoke CH, 1994 A live attenuated dengue-1 vaccine candidate (45AZ5) passaged in primary dog kidney cell culture is attenuated and immunogenic for humans J Infect Dis 170: 1448-1455.
19. Brandt WE, 1990 Development of dengue and Japanese encephalitis vaccines. J Infect Dis 162: 577-583.
20. Putnak R, 1994. Progress in the development of recombinant vaccines against dengue and other arthropod-borne flaviviruses. Kurstak E, ed. Modem Vaccinology. New York: Plenum Medical. 11: 231-252.
21. Takaku K, Yamashita T, Osanai T, Yoshida I, Kato M, Goda H, Takagi M, Hirota T, Amano T, Fukai K, Kunita N, Inoue K, Choji K, Igarashi A, Ito T, 1968. Japanese encephalitis purified vaccine. Biken J 11: 25-39.
22. Hoke CH, Nisalak A, Sangawhipa N, Jatanasen S, Laorakongse T, Innis BL, Kotchasensee S, Gingrich JB, Latendresse J, Fukai K, Burke DS, 1988. Protection against Japanese encephalitis by inactivated vaccines. N Engl J Med 319: 608-613.
23. Kunz C, Heinz FX, Hofmann H, 1980. Immunogenicity and rcactogenicity of a highly purfied vaccine against tick-borne encephalitis. J Med Virol 6: 103-109
24. Brandt WE, Buescher EL, Hetrick FM, 1967. Production and characterization of arbovirus antibody in mouse ascitic fluid. Am J Trop Med Hyg 16: 339-347.
25. Henchal EA, McCown JM, Seguin MC, Gentry MK, Brandt WE, 1983. Rapid identification of dengue virus isolates by using monoclonal antibodies in an indirect immunofluorescence assay. Am J Trop Med Hyg 32: 164-200.
26. Henchal EA, McCown JM, Burke DJ, Seguin MC, Brandt WE. 1985. Eptiopic analysis of antigenic determinants on the surface of dengue 2 virions using monoclonal antibodies. Am J Trop Med Hyg 34: 162-167.
27. Russell PK, Nisalak A, Sukhavachana P, Vivona S. 1967. A plaque reduction test for dengue virus neutralizing antibodies. J Immunol 99, 285-290.
28. Chappell WA, Sasso DR, Toole RF, Monath TP. 1971. Labile serum and its effect on arbovirus neutralization. Appl Microbiol 21: 79-83.
29. Burnette WN, 1981. "Western blotting": electrophoretic transfer of proteins from sodium dodecyl sulfate-polyacrylamide gels to unmodified nitrocellulose and radiographic detection with antibody and radioiodinated protein A. Anal Biochem 112: 195-203.
30. Klockmann U, Bock HL, Franke V, Hein B, Reiner G, Hilfen-haus J, 1989. Preclinical investigations of the safety, immunogenicity and efficacy of a purified, inactivated tick-borne encephalitis vaccine. J Biol Stand 17: 331-342.
31. Yamashita T, Ishikawa N, Hojo F, Shimada F, Ono K, Takagi M, Kato M, Takaku K, Amano T, Fujio H, Inoue K, Kato S, 1970. Japanese encephalitis purified vaccine. II Purity of the mouse brain vaccine purified by ultracentrifugation. Biken J 13: 25-38.